Why Revvity, Inc. (RVTY) Stock Rose 9.1% on Sep 15, 2026
The clearest new catalyst: Analyst Price-Target Hikes.
Why did RVTY stock rise?
Revvity surged 9.1% on September 15, 2026, driven by major analyst price-target hikes from KeyBanc (to $165) and Baird (to $144), citing robust AI-driven screening demand in life science tools. The rally was reinforced by the company's presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, which highlighted confidence in its recent earnings beat-and-raise trajectory, and by positive sentiment around the pending acquisition of France-based Human Cell Design, which expands the company's footprint in diabetes and obesity research platforms.
- Analyst Price-Target Hikes: KeyBanc raised its price target to $165 (from $125) and Baird raised its target to $144, both citing robust AI-driven screening demand in life science tools and confidence in the company's growth trajectory.
- Morgan Stanley Healthcare Conference Presentation: Revvity's presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 reinforced investor confidence in the company's recent earnings beat-and-raise performance and AI platform capabilities.
- Human Cell Design Acquisition: The pending acquisition of France-based Human Cell Design, which introduces advanced human pancreatic beta cell models and GLP-1–linked platforms, boosted sentiment by expanding the company's footprint in high-demand diabetes and obesity research.
- Recent Earnings Beat and Guidance Raise: The company's earlier quarterly earnings beat (EPS $1.41 vs. consensus) and raised full-year guidance provided the underlying momentum that analysts referenced in their September 15 upgrades.
Initial detection
BestStocks first flagged RVTY intraday on Sep 15, 2026; this analysis was finalized after the close using the confirmed +9.1% session move and additional catalyst research.
Show the initial intraday note
Revvity surged +7.55% to $138.19, driven by strong momentum following a recent quarterly earnings beat (EPS $1.41 vs. consensus), raised full-year guidance, and positive analyst sentiment on Diagnostics growth and AI platform integration with Anthropic's Claude, per Yahoo Finance and the web catalyst. Volume of 1.25M shares traded at 1.30x the time-adjusted average, indicating above-normal conviction.
What to watch next: Revvity earnings scheduled for October 26, 2026 (consensus EPS estimate $1.29); monitor whether management maintains or adjusts full-year guidance given current momentum.
Frequently asked questions
Why did Revvity, Inc. (RVTY) stock rise on Sep 15, 2026?
Revvity surged 9.1% on September 15, 2026, driven by major analyst price-target hikes from KeyBanc (to $165) and Baird (to $144), citing robust AI-driven screening demand in life science tools. The rally was reinforced by the company's presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, which highlighted confidence in its recent earnings beat-and-raise trajectory, and by positive sentiment around the pending acquisition of France-based Human Cell Design, which expands the company's footprint in diabetes and obesity research platforms.
How much did RVTY stock rise on Sep 15, 2026?
RVTY rose 9.1% during the Sep 15, 2026 trading session.
What were the main drivers behind RVTY's move?
Analyst Price-Target Hikes; Morgan Stanley Healthcare Conference Presentation; Human Cell Design Acquisition; Recent Earnings Beat and Guidance Raise.